Teva Pharmaceutical Industries Ltd. announced the Food and Drug Administration approval and the launch of the generic equivalent to Diovan (Valsartan) Tablets in the United States. Diovan (Valsartan) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $1.8 billion in the United States.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.25 USD | -0.06% |
|
-4.19% | +55.65% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.65% | 18.4B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Launches Generic Diovan® in the United States